Comparative efficacy and safety of two regional citrate anticoagulation protocols in hemodialysis: a randomized, open-label, cross-over controlled study

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000034314

Enrollment

Unknown

Registered

2020-07-01

Start date

2020-08-01

Completion date

Unknown

Last updated

2020-09-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hemodialysis

Interventions

Group A:phase I: S-RCA

phase II: TS-RCA

Group B:phase I: TS-RCA

phase II: S-RCA.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Aged over 18 years; 2. Patients who need hemodialysis due to renal insufficiency 3. Patients evaluated by more than 2 clinicians who believe that heparin or low molecular weight heparin anticoagulation should not be used for anticoagulation.

Exclusion criteria

Exclusion criteria: 1. With significant impairment of liver function 2. With Irreversible hypoxemia (PO2 2.8mmol/l); 4. A history of sodium citrate allergies; 5. Any other serious conditions judged by the clinicians.

Design outcomes

Primary

Measure	Time frame
Coagulation of dialyzers and venous ampoules;	—

Secondary

Measure	Time frame
Blood routine;Blood chemistry;blood gas analysis;blood gas analysis;PT;APTT;hypercalcemia;Kt/V;hypocalcemia;metabolic alkalosis;Other adverse events;	—

Countries

China

Contacts

Public ContactLiu Yueming

Department of Nephrology, Zhejiang Provincial People's Hospital

lyman6136@126.com+86 18857150096

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026